The DOI matches its Crossref record; 240 of the 242 references it cites were found in a registry or an index.
Role of integrated cancer nanomedicine in overcoming drug resistance
Abstract
Cancer remains a major killer of mankind. Failure of conventional chemotherapy has resulted in recurrence and development of virulent multi drug resistant (MDR) phenotypes adding to the complexity and diversity of this deadly disease. Apart from displaying classical physiological abnormalities and aberrant blood flow behavior, MDR cancers exhibit several distinctive features such as higher apoptotic threshold, aerobic glycolysis, regions of hypoxia, and elevated activity of drug-efflux transporters. MDR transporters play a pivotal role in protecting the cancer stem cells (CSCs) from chemotherapy. It is speculated that CSCs are instrumental in reviving tumors after the chemo and radiotherapy. In this regard, multifunctional nanoparticles that can integrate various key components such as drugs, genes, imaging agents and targeting ligands using unique delivery platforms would be more efficient in treating MDR cancers. This review presents some of the important principles involved in development of MDR and novel methods of treating cancers using multifunctional-targeted nanoparticles. Illustrative examples of nanoparticles engineered for drug/gene combination delivery and stimuli responsive nanoparticle systems for cancer therapy are also discussed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Due to the enhanced permeability and retention effect (EPR effect), 174 selective accumulation in solid tumors can be used to target hypoxic tumors more effectively.”
From Hypoxia signaling in cancer: Implications for therapeutic interventions (2023) · cites this paper as [175]
Citations
Cites
Prospective identification of tumorigenic breast cancer cells
Al‐Hajj, M., Wicha, M. S., Benito‐Hernández, A., Morrison, S. J., & Clarke, M. F. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0530291100 · Cited by 10,579
Stem cells, cancer, and cancer stem cells
Reya, T., Morrison, S. J., Clarke, M. F., & Weissman, I. L. (2001) · Nature · doi:10.1038/35102167 · Cited by 9,738
Bonnet, D. A., & Dick, J. E. (1997) · Nature Medicine · doi:10.1038/nm0797-730 · Cited by 7,197
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Epithelial–mesenchymal transitions in tumour progression
Thiery, J. P. (2002) · Nature reviews. Cancer · doi:10.1038/nrc822 · Cited by 6,767
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536
Recent advances with liposomes as pharmaceutical carriers
Torchilin, V. P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1632 · Cited by 5,282
Hypoxia — a key regulatory factor in tumour growth
Harris, A. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc704 · Cited by 5,177
Schafer, F. Q., & Buettner, G. R. (2001) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(01)00480-4 · Cited by 4,587
Research works printed but not linked: 3
- Hortobagyi, 1997, Anthracyclines in the treatment of cancer. An overview, Drugs, 54, 1
- Jabr-Milane, 2008, Multi-functional nanocarriers to overcome tumor drug resistance, Cancer Treat. Rev., 34, 592, 10.1016/j.ctrv.2008.04.003 · DOI
- Lavignac, 2004, Synthesis and endosomolytic properties of poly(amidoamine) block copolymers, Macromol. Biosci., 4, 922, 10.1002/mabi.200400093 · DOI
Cited by
Sorted by citations
Cancer nanomedicine: from targeted delivery to combination therapy
Xu, X., Ho, W., Zhang, X., Bertrand, N., & Farokhzad, O. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.01.001 · Cited by 693
Hyaluronic acid targeting of CD44 for cancer therapy: from receptor biology to nanomedicine
Mattheolabakis, G., Milane, L., Singh, A., & Amiji, M. M. (2015) · Journal of Drug Targeting · doi:10.3109/1061186x.2015.1052072 · Cited by 597
Self-citationNanoparticles in Drug Delivery: From History to Therapeutic Applications
Afzal, O., Altamimi, A. S. A., Nadeem, M. S., Alzarea, S. I., Almalki, W. H., Tariq, A., Mubeen, B., Murtaza, B. N., Iftikhar, S., Riaz, N., et al. (2022) · Nanomaterials · doi:10.3390/nano12244494 · Cited by 468
Cancer stem cell (CSC) resistance drivers
Najafi, M., Mortezaee, K., & Majidpoor, J. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.116781 · Cited by 485
Biological agents for synthesis of nanoparticles and their applications
Pandit, C., Roy, A., Ghotekar, S. K., Khusro, A., Islam, M. N., Emran, T. B., Lam, S. E., Khandaker, M. U., & Bradley, D. A. (2022) · Journal of King Saud University - Science · doi:10.1016/j.jksus.2022.101869 · Cited by 454
Metadata
- Authors
- Iyer, A. K., Singh, A., Ganta, S., & Amiji, M. M.
- Affiliations
- Northeastern University (US)
- Nemucore Medical Innovations (United States) (US)
- Corresponding author
- Amiji, Mansoor M.
- Venue
- Advanced Drug Delivery Reviews
- Publisher
- Elsevier BV
- Published
- 2013-11
- Volume
- 65
- Issue
- 13-14
- Pages
- 1784-1802
- ISSN
- 0169-409X (ISSN-L)
- OpenAlex
- W2000798536
- Cited by
- 343
- References
- 242
- Citations by year
- 2026: 6 · 2025: 16 · 2024: 31 · 2023: 26 · 2022: 28 · 2021: 32 · 2020: 26 · 2019: 33 · 2018: 30 · 2017: 31 · 2016: 33 · 2015: 23 · 2014: 27 · 2013: 1
- FWCI
- 1.90
- Type
- journal article
- Language
- en
- Update notices
- Open access
- closed
- Locations
- Advanced Drug Delivery Reviews (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
- Keywords
- cancer nanomedicine, multidrug resistance, drug resistance, multifunctional nanoparticles, targeted drug delivery, cancer stem cells, efflux pumps, stimuli-responsive nanoparticles, tumor hypoxia, aerobic glycolysis, tumor recurrence
- MeSH terms
- Animals, Antineoplastic Agents, Drug Carriers, Humans, Neoplasms, Drug Delivery Systems, Drug Resistance, Neoplasm, Nanomedicine, Nanoparticles, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
